An interim analysis of a clinical trial of Merck & Co. and NewLink Genetics' Ebola vaccine showed that the vaccine has so far provided 100% protection from the deadly haemorrhagic virus. In the 'cluster-randomized ring vaccination trial', clinicians identified contacts of confirmed Ebola cases and randomly assigned each cluster to either immediate treatment with rVSV-ZEBOV or to delayed treatment, 21 days later. There were 0 cases of Ebola in the 4,100 people who received immediate vaccination, compared with 16 cases of Ebola in the 3,500 people who received delayed vaccination (Lancet, published online 3 Aug 2015). Further trials are ongoing to determine whether the promising interim findings hold up.
The data also provide proof of concept for the cluster-randomized ring vaccination trial design, which could be useful for the development of vaccines against other viral outbreaks.
Merck's rVSV-ZEBOV consists of a recombinant, replication-competent vesicular stomatitis virus that expresses the glycoprotein of Zaire Ebola virus. GlaxoSmithKline and Johnson & Johnson also have Ebola vaccines in clinical development.
Rights and permissions
About this article
Cite this article
Mullard, A. Ebola vaccine yields first hopes of clinical efficacy. Nat Rev Drug Discov 14, 593 (2015). https://doi.org/10.1038/nrd4732
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4732